A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Clinical trial NCT07373964 · RECRUITING
Trial details
- NCT number
- NCT07373964
- Sponsor
- China Medical University, China
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-15
- Primary completion
- 2026-10-14
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.